These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30835635)

  • 1.
    Hagiya H; Aoki K; Akeda Y; Yamamoto N; Shanmugakani RK; Ishii Y; Tomono K
    Microb Drug Resist; 2019; 25(6):839-845. PubMed ID: 30835635
    [No Abstract]   [Full Text] [Related]  

  • 2. In Vitro Efficacy of Meropenem-Cefmetazole Combination Therapy against New Delhi Metallo-β-lactamase-producing Enterobacteriaceae.
    Hagiya H; Sugawara Y; Tsutsumi Y; Akeda Y; Yamamoto N; Sakamoto N; Shanmugakani RK; Abe R; Takeuchi D; Nishi I; Ishii Y; Hamada S; Tomono K
    Int J Antimicrob Agents; 2020 Mar; 55(3):105905. PubMed ID: 31991221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae.
    Abe R; Hagiya H; Akeda Y; Yamamoto N; Ishii Y; Tomono K
    BMC Res Notes; 2019 Nov; 12(1):740. PubMed ID: 31706328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant
    Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q
    Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
    Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
    Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
    Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains.
    Erdem F; Abulaila A; Aktas Z; Oncul O
    Antimicrob Resist Infect Control; 2020 May; 9(1):70. PubMed ID: 32430058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency Determination of Carbapenem-Resistant Klebsiella Pneumoniae (CRKP) Isolated from hospitals in Isfahan of Iran and Evaluation of Synergistic Effect of Colistin and Meropenem on them.
    Gheitani L; Fazeli H; Moghim S; Nasr Isfahani B
    Cell Mol Biol (Noisy-le-grand); 2018 Jan; 64(1):70-74. PubMed ID: 29412797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo study assessed meropenem and amikacin combination therapy against carbapenem-resistant and carbapenemase-producing Enterobacteriaceae strains.
    Hagihara M; Kato H; Yamashita R; Soda M; Watanabe H; Sakanashi D; Shiota A; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Kitaichi K; Mikamo H
    J Infect Chemother; 2020 Jan; 26(1):1-7. PubMed ID: 31735629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of
    Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
    Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibacterial activity and carbapenem re-sensitizing ability of 1,10-phenanthroline-5,6-dione and its metal complexes against KPC-producing Klebsiella pneumoniae clinical strains.
    Vianez Peregrino I; Ferreira Ventura R; Borghi M; Pinto Schuenck R; Devereux M; McCann M; Souza Dos Santos AL; FerreiraNunes AP
    Lett Appl Microbiol; 2021 Aug; 73(2):139-148. PubMed ID: 33843058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro synergy of β-lactam combinations against KPC-producing Klebsiella pneumoniae strains.
    Lawandi A; Leite G; Cheng MP; Lefebvre B; Longtin J; Lee TC
    J Antimicrob Chemother; 2019 Dec; 74(12):3515-3520. PubMed ID: 31730163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitro-Carba test, a novel and simple chromogenic phenotypic method for rapid screening of carbapenemase-producing Enterobacteriaceae.
    Teethaisong Y; Nakouti I; Evans K; Eumkeb G; Hobbs G
    J Glob Antimicrob Resist; 2019 Sep; 18():22-25. PubMed ID: 30668995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efflux pump inhibitor phenylalanine-arginine β-naphthylamide (PAβN) increases resistance to carbapenems in Chilean clinical isolates of KPC-producing Klebsiella pneumoniae.
    Vera-Leiva A; Carrasco-Anabalón S; Lima CA; Villagra N; Domínguez M; Bello-Toledo H; González-Rocha G
    J Glob Antimicrob Resist; 2018 Mar; 12():73-76. PubMed ID: 29275225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis.
    Tattevin P; Dinh A; Ghout I; Mouton W; Verdier MC; Laurent F; Lemaitre F; Gatin L; Saleh-Mghir A; Crémieux AC
    Int J Antimicrob Agents; 2020 Nov; 56(5):106152. PubMed ID: 32898684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.
    Hong JH; Clancy CJ; Cheng S; Shields RK; Chen L; Doi Y; Zhao Y; Perlin DS; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2013 May; 57(5):2147-53. PubMed ID: 23459476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.